Sihuan Pharmaceutical (HKG:0460) said five new specifications of the Hyaluronic Acid Sodium Composite Solution for Injection were approved for launch by China's National Medical Products Administration.
The composite solution skin booster was developed by unit Meiyan Space Biotechnology (Jilin), a Monday bourse filing showed.
The specification expansion will allow adaptation to diverse skin needs and clinical application scenarios among other benefits.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.